NEXI
Price:
$0.279
Market Cap:
$389.11K
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted...[Read more]
Industry
Biotechnology
IPO Date
2021-02-12
Stock Exchange
NASDAQ
Ticker
NEXI
According to NexImmune, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is -2034999.00. This represents a change of 43.96% compared to the average of -4618.48 of the last 4 quarters.
The mean historical Enterprise Value of NexImmune, Inc. over the last ten years is 309.49M. The current -2034999.00 Enterprise Value has changed -165.75% with respect to the historical average. Over the past ten years (40 quarters), NEXI's Enterprise Value was at its highest in in the December 2020 quarter at 639.97M. The Enterprise Value was at its lowest in in the September 2022 quarter at -31148672.56.
Average
309.49M
Median
332.73M
Minimum
-27766353.88
Maximum
614.97M
Discovering the peaks and valleys of NexImmune, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.63%
Maximum Annual Enterprise Value = 614.97M
Minimum Annual Increase = -137.06%
Minimum Annual Enterprise Value = -27766353.88
Year | Enterprise Value | Change |
---|---|---|
2023 | -803824.04 | -97.11% |
2022 | -27766353.88 | -137.06% |
2021 | 74.91M | -87.31% |
2020 | 590.54M | -3.97% |
2019 | 614.97M | 1.63% |
The current Enterprise Value of NexImmune, Inc. (NEXI) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
15.45M
5-year avg
250.37M
10-year avg
309.49M
NexImmune, Inc.’s Enterprise Value is less than ZyVersa Therapeutics, Inc. (2.62M), greater than Palisade Bio, Inc. (-2842535.00), less than Unicycive Therapeutics, Inc. (37.28M), greater than Apexigen, Inc. (-5121682.00), less than Immix Biopharma, Inc. (41.37M), less than TransCode Therapeutics, Inc. (769.13K), less than Landos Biopharma, Inc. (42.62M), less than Oncorus, Inc. (42.71M), less than Xenetic Biosciences, Inc. (-532207.00), less than eFFECTOR Therapeutics, Inc. (4.74M), greater than Virios Therapeutics, Inc. (-2813681.00), greater than Zura Bio Limited (-32822399.00), greater than Navidea Biopharmaceuticals, Inc. (-2595051.00), less than CNS Pharmaceuticals, Inc. (-675887.00), less than Sonnet BioTherapeutics Holdings, Inc. (4.31M), less than Mereo BioPharma Group plc (445.16M), less than Terns Pharmaceuticals, Inc. (234.86M), less than PDS Biotechnology Corporation (37.39M), less than Inozyme Pharma, Inc. (215.58M), greater than HOOKIPA Pharma Inc. (-37325309.00),
Company | Enterprise Value | Market cap |
---|---|---|
2.62M | $2.74M | |
-2842535.00 | $4.84M | |
37.28M | $68.82M | |
-5121682.00 | $9.57M | |
41.37M | $59.97M | |
769.13K | $2.49M | |
42.62M | $71.68M | |
42.71M | $0 | |
-532207.00 | $6.31M | |
4.74M | $941.00 | |
-2813681.00 | $206.50K | |
-32822399.00 | $155.40M | |
-2595051.00 | $10.01K | |
-675887.00 | $6.27M | |
4.31M | $4.33M | |
445.16M | $524.55M | |
234.86M | $503.69M | |
37.39M | $62.47M | |
215.58M | $193.36M | |
-37325309.00 | $19.60M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like NexImmune, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like NexImmune, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is NexImmune, Inc.'s Enterprise Value?
What is the highest Enterprise Value for NexImmune, Inc. (NEXI)?
What is the 3-year average Enterprise Value for NexImmune, Inc. (NEXI)?
What is the 5-year average Enterprise Value for NexImmune, Inc. (NEXI)?
How does the current Enterprise Value for NexImmune, Inc. (NEXI) compare to its historical average?